deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT02701088

Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life (CANAL-IMRT-01)

Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life

Sponsor: Accuray Incorporated

Conditions Locally Advanced Anal Canal Cancer
Interventions 5Fluorouracile and Mitomycin-C Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy
Updated 18 times since 2017 Last updated: Sep 17, 2025 Started: Dec 31, 2015 Primary completion: Jun 25, 2021 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02701088, this PHASE2 trial focuses on Locally Advanced Anal Canal Cancer and remains ongoing. Sponsored by Accuray Incorporated, it has been updated 18 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Sep 2017 · 8 months · monthly snapshot~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Mar 2020 · 13 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Oct 2020 · 6 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Jan 2023 · 14 months · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 11 months · monthly snapshot

Change History

18 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 13 earlier versions

  1. Nov 2021 — Jan 2023 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  2. Oct 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Apr 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  7. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  8. Feb 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  9. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  11. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Suspended → Recruiting

  12. Sep 2017 — Jan 2018 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  13. Jan 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Accuray Incorporated
  • Centre Francois Baclesse
Data source: Centre Francois Baclesse

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations